|
|
 |
|
Viewing report
|
|
|
|
Global Generics Guide: Capitalizing On an $82 Billion Opportunity
Datamonitor, Aug 2002
The generics industry is facing a period of unprecedented growth, with $82 billion worth of global blockbusters set to face US patent expiry by 2007.
The changing dynamics of the generics market are driving strategic evolution of leading players, with portfolio management, geographic expansion and alliance networks determining success and failure. The Global Generics Guide analysis provides you with the insight needed to understand the changing dynamics within the global generics market to 2007.
The report includes:
- Benchmarking of leading players in the generics market by 2001 sales, profits and R&D spend and by forecast generic sales between 2002 and 2007
- In-depth analysis of portfolio management, geographical expansion and partnership strategies and assessment of winners and losers
- Full profiles of 10 of the leading generics companies- Alpharma, Andrx, Barr, Ivax, KV Pharmaceuticals, Mylan, Ranbaxy, Sicor, Teva and WatsonOne, three and six year forecasts for key products and total ethical sales for 10 generics companies, benchmarked against analyst consensus estimates
The global generics market is forecast to significantly outperform the branded sector in terms of sales growth between 2002 and 2007. While Teva will maintain its lead at the head of the generics market, the chasing pack will see changing fortunes as the boom and bust of paragraph IV filings take their toll. Europe is set to outperform the US in terms of overall growth and companies capitalizing on expanding opportunities in Southern Europe will see their efforts rewarded by 2007. Rising competition from Indian and Eastern European low cost providers will augment the pressure on margins, forcing Western players to add value through specialty generics and supergenerics.
Benchmark your strategy against key rivals in the generics sector. Assess the timescale and impact of biogenerics on your business. Understand the drivers of growth in the major generics markets and their impact on the branded sector. Realize the benefits and limitations of alliance networks with generics companies. Effectively implement portfolio management strategies to maximize profit return.
Customers who bought this item also bought
Pharmavitae Generics - Teva
Generics Review 2000/ 2001
Br Malls Participacoes Sa
Br. Holdings Corporation
PharmaVitae 2001: Teva Pharmaceutical Industries
Mylan: PharmaVitae Generics Profile
PharmaVitae 2001: Alpharma Inc.
Barr: PharmaVitae Generics Profile
Watson: PharmaVitae Generics Profile
Global Generics Guide 2nd Edition: Optimizing Geographical and Strategic Positioning in an Evolving Generics Landscape
Generics: Global Industry Guide
Q2 2008 Earnings Call - BR Malls Participaçoes SA, - Earnings Transcript
|
|
|
|
